These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26813950)

  • 1. Prostate cancer: Testosterone-guided ADT for prostate cancer.
    Nishiyama T; Hoshii T
    Nat Rev Urol; 2016 Apr; 13(4):189-91. PubMed ID: 26813950
    [No Abstract]   [Full Text] [Related]  

  • 2. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
    Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
    Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The question of intermittent hormonal treatment of cancer of the prostate].
    Boca P
    Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121
    [No Abstract]   [Full Text] [Related]  

  • 5. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?
    Mottet N
    Eur Urol; 2013 Jan; 63(1):121-2; discussion 123-4. PubMed ID: 22921963
    [No Abstract]   [Full Text] [Related]  

  • 6. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

  • 7. Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
    Wolff JM; Abrahamsson PA; Irani J; da Silva FC
    BJU Int; 2014 Oct; 114(4):476-83. PubMed ID: 24433259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
    Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
    Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer--management of disseminated disease (intermittent androgen suppression).
    Lobel B; Richard F
    Acta Chir Iugosl; 2005; 52(4):11-2. PubMed ID: 16673586
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy and prostate cancer duration.
    Williams SG; Pickles T; Buyyounouski MK
    J Clin Oncol; 2009 Dec; 27(34):e228; author reply e229. PubMed ID: 19884533
    [No Abstract]   [Full Text] [Related]  

  • 12. Intermittent versus continuous androgen deprivation treatment of prostate cancer.
    Zhu J; Zheng Y
    J Clin Oncol; 2013 Nov; 31(31):4024. PubMed ID: 24062402
    [No Abstract]   [Full Text] [Related]  

  • 13. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent androgen suppression--ready for prime time?
    Ischia J; Goldenberg SL
    J Urol; 2012 Jun; 187(6):1956-7. PubMed ID: 22503023
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Penson DF
    J Urol; 2016 Feb; 195(2):353. PubMed ID: 26852977
    [No Abstract]   [Full Text] [Related]  

  • 16. [Intermittent hormonal treatment in prostatic cancer].
    Zerbib M; Conquy S
    Prog Urol; 1997 Dec; 7(6):1026-7. PubMed ID: 9490134
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 18. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Words of wisdom: Re: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
    Tombal B
    Eur Urol; 2014 May; 65(5):1013-4. PubMed ID: 24646499
    [No Abstract]   [Full Text] [Related]  

  • 20. Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?
    Park JC; Eisenberger MA
    J Clin Oncol; 2016 Jan; 34(3):211-4. PubMed ID: 26628474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.